XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.2Close
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
EXPENSES    
General and administrative $ 1,057,364 $ 1,368,999
Research and development 364,385 1,281,817
Total expenses 1,421,749 2,650,816 Close
LOSS FROM OPERATIONS (1,421,749) (2,650,816) Close
OTHER EXPENSE (INCOME), NET    
Loss (gain) on change in fair value of warrant liabilities 133,300 (1,038,673)
Gain on change in fair value of derivative liabilities (164,497)
Interest expense , net 136,556 544,238
Loss on issuance of convertible debt 358,279
Loss on voluntary conversion of convertible debt into common stock 1,077,287
Loss on monthly redemptions of convertible debt into common stock 147,197
Other income, net (1,619)
Total other expense (income), net 609,216 582,852 Close
LOSS BEFORE PROVISION FOR INCOME TAXES (2,030,965) (3,233,668) Close
PROVISION FOR INCOME TAXES (1,786) (1,393) Close
NET LOSS FROM CONTINUING OPERATIONS (2,032,751) (3,235,061)
DISCONTINUED OPERATIONS    
Loss from discontinued operations, net of tax (872,188)
LOSS FROM DISCONTINUED OPERATIONS (872,188) Close
NET LOSS (2,032,751) (4,107,249) Close
Net loss attributable to non-controlling interest from discontinued operations (261,028)
Net loss available to Qualigen Therapeutics, Inc. (2,032,751) (3,846,221)
Deemed dividend arising from warrant down-round provision (60,017)
Net loss attributable to Qualigen Therapeutics, Inc $ (2,092,768) $ (3,846,221)
Net loss per common share, basic - continuing operations $ (0.35) $ (0.65)
Net loss per common share, diluted - continuing operations (0.35) (0.65)
Net loss per common share, basic - discontinued operations (0.12)
Net loss per common share, diluted - discontinued operations $ (0.12)
Weighted-average number of shares outstanding, basic 5,943,814 4,959,122
Weighted-average number of shares outstanding, diluted 5,943,814 4,959,122
Other comprehensive loss, net of tax    
Net loss $ (2,032,751) $ (4,107,249)
Foreign currency translation adjustment from discontinued operations 119,723
Other comprehensive loss (2,032,751) (3,987,526)
Comprehensive loss attributable to noncontrolling interest from discontinued operations (261,028)
Comprehensive loss attributable to Qualigen Therapeutics, Inc. $ (2,032,751) $ (3,726,498)